Ashanti and Nelly Are Engaged and Expecting a Baby
It’s a match made in Top 40 radio: musicians Ashanti and Nelly are engaged and expecting their first child together, Ashanti shared with Essence Wednesday. “This new year of my life is such a blessing full of love, hope, and anticipation,” she told the outlet. “Motherhood is something that I have…#ashanti #nelly #rb #grammy #jackiedonahue #leukemia #proov #instagramandessences (Source: Reuters: Health)
Source: Reuters: Health - April 18, 2024 Category: Consumer Health News Source Type: news
Ending Specialized Follow-Up Feasible in Asymptomatic, Low-Risk Leukemia
THURSDAY, April 18, 2024 -- For select patients with asymptomatic, lower-risk chronic lymphocytic leukemia, ending specialized follow-up (sFU) is feasible and safe, according to a study published in the March 1 issue of Blood Advances.Christian... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2024 Category: Pharmaceuticals Source Type: news
ALL: Which Life-Saving Tx Is Best? ALL: Which Life-Saving Tx Is Best?
New treatments like bispecific antibodies and CAR T-cell therapy have helped many patients with relapsed/refractory acute lymphoblastic leukemia live longer but which is best?MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2024 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Can Older Patients With Low-Risk Leukemia Quit Seeing Specialists?
TUESDAY, April 8, 2024 -- Some slow-growing cases of leukemia don ’t need constant surveillance by cancer specialists, a new study claims.Low-risk patients with slow-growing chronic lymphocytic leukemia (CLL) and no symptoms fared well even after... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2024 Category: General Medicine Source Type: news
PET/MRI detects brain injury in pediatric cancer survivors
PET/MRI could be a tool for diagnosing brain injury in young cancer survivors due to high-dose methotrexate treatment, according to pediatric radiologists at Stanford University in Stanford, CA.
In a pilot study in 10 children and young adults, F-18 FDG-PET/MRI detected brain injury based on reductions in glucose metabolism and blood flow in specific brain areas. The imaging findings could facilitate earlier treatments in these patients, noted lead author Lucia Baratto, MD, and colleagues.
“Using F-18 FDG-PET/MRI for assessing the cerebral impact of methotrexate therapy in pediatric cancer survivors holds the potential...
Source: AuntMinnie.com Headlines - April 8, 2024 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
New study paves the way for precision drugs to treat blood cancers
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain. (Source: World Pharma News)
Source: World Pharma News - April 4, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Johns Hopkins investigators develop novel treatment for T-cell leukemias and lymphomas
A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.
The therapy, an antibody-drug conjugate (ADC), combines an antibody that targets a protein called TRBC1 expressed on the surface of T-cell cancers with an anti-cancer drug, called SG3249. (Source: World Pharma News)
Source: World Pharma News - April 3, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
CAR T-Cell Therapy: What You Should Know Today
CAR T-cell therapy could be lifesaving if your leukemia or¬ lymphoma hasn’t responded to other treatments. Find out how this therapy works and what to expect. (Source: WebMD Health)
Source: WebMD Health - April 2, 2024 Category: Consumer Health News Source Type: news
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
DUBLIN, March 29, 2024 /PRNewswire/ -- The "Global Acute Lymphoblastic Leukemia Therapeutics Market: Focus on Cell Type, Therapy Type, and Over 10 Countries' Data - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering. The global market for Acute... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 29, 2024 Category: Pharmaceuticals Tags: MRR Source Type: news
BusinessWoman of the Year 2024: Rebecca Siviglia of H. Lee Moffitt Cancer Center and Research Institute
Siviglia serves in leadership at the American Cancer Society, the Leukemia and Lymphoma Society, and the Tampa Bay Chamber of Commerce. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 29, 2024 Category: Biotechnology Authors: Brooke Strickland Source Type: news
Improvements Seen in Post-Allo-HCT Outcomes for Seniors With Leukemia
THURSDAY, March 28, 2024 -- For older patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT), posttransplant outcomes have improved over time, according to a study published online March 22 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2024 Category: Pharmaceuticals Source Type: news
Breastfeeding Tied to Reduced Childhood Leukemia Risk
(MedPage Today) -- Longer duration of exclusive breastfeeding was associated with a reduced risk of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to results from a Danish population-based cohort study.
Compared with... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 27, 2024 Category: Hematology Source Type: news
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
WALTHAM, Mass., March 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 26, 2024 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Frontline Regimen for Aggressive ALL
(MedPage Today) -- The FDA granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in previously untreated adults, the agency announced this... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 22, 2024 Category: American Health Source Type: news
Predicting Risk for Secondary Leukemia after PARPi Therapy Predicting Risk for Secondary Leukemia after PARPi Therapy
A new study pinpointed potential predictive factors for secondary myelodysplastic syndrome or acute myeloid leukemia after PARP inhibitor therapy in women with ovarian cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
